en
Scientific article
Open access
English

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Published inCancer Biology and Therapy, vol. 21, no. 3, p. 197-202
Publication date2020
Abstract

Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patients.Initial trials with palbociclib in serous ovarian cancer have shown very modest benefit in unselected patient populations, thus underlining the need for a biomarker predicting response. We report the case of a heavily pre-treated patient with a serous ovarian tumor harboring a homozygous deletion of the CDKN2A gene that derived significant, prolonged clinical benefit from palbociclib, a CDK4/6 oral inhibitor, with letrozole. Treatment with palbociclib and letrozole started on February 2018, with an ongoing response after 12 months.In conclusion, homozygous CDKN2A deletion is rare and could be used to predict response to CDK4/6 inhibitors in association with other genomic features. We encourage further trials in this direction.

Citation (ISO format)
FRISONE, Daniele et al. Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. In: Cancer Biology and Therapy, 2020, vol. 21, n° 3, p. 197–202. doi: 10.1080/15384047.2019.1685291
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1538-4047
252views
105downloads

Technical informations

Creation11/30/2020 4:59:00 PM
First validation11/30/2020 4:59:00 PM
Update time03/15/2023 11:38:49 PM
Status update03/15/2023 11:38:48 PM
Last indexation05/05/2024 5:48:40 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack